Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
FMS vs GMAB — Stock Comparison
Compare FMS and GMAB side-by-side on StoQuant: FMS Q-Score 50 vs GMAB 50; analyst signal 50 vs 50. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- FMS — Fresenius Medical Care AG & Co. KGaA · Health Care · market cap $11.22B · Q-Score verdict Unrated (50.0) · analyst signal 50/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: ML forecast 73/100, technicals 35/100 · weakest signals: analyst consensus 15/100. Full FMS research.
- GMAB — Genmab A/S · Health Care · market cap $22.13B · Q-Score verdict Unrated (50.0) · analyst signal 50/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: ML forecast 79/100, technicals 63/100 · weakest signals: analyst consensus 15/100. Full GMAB research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: FMS research · GMAB research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →